Single Blind Randomized Phase III Trial to Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
Phase 3
Recruiting
- Conditions
- prostate cancer1003858810018188
- Registration Number
- NL-OMON44824
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 506
Inclusion Criteria
Patients with intermediate or high risk local prostate cancer
WHO 0-2
Exclusion Criteria
Low risk prostate cancer
WHO score >2
If an MRI cannot be performed
IPSS score >20
Previous pelvic irradiation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To decrease the five-year biochemical relapse rate with at least 10%.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Does the addition of an ablative microboost to the macroscopic tumour within<br /><br>the prostate change treatment related toxicity, quality of life or disease free<br /><br>survival.</p><br>